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Elective total parathyroidectomy without autotransplant in end-stage
renal disease. Ten patients are reported following parathyroidectomy
(PTX). In 9 all identifiable parathyroid tissue in the neck was deliber-
ately removed, and in the tenth (operated 14 years ago) the remnant
which had been left probably did not function. Their post-operative
course resembled that of patients treated conventionally, and their
subsequent course was likewise uneventful with disappearance of all
symptoms associated with their osteodystrophy. All patients required
oral calcium supplementation but none were given vitamin D com-
pounds after the initial period of repletion following surgery. Mean
serum values were (before PTX and current) for calcium 2.63 0.14
and 2.33 0.08 mmol/liter, P = NS, for phosphorus 1.96 0.13 and
1.38 0.09 mmol/liter, P < 0.01. and for alkaline phosphatase 713
191 and 101 14 IU, P < 0.05. Evidence for residual parathyroid tissue
was present in each case; one patient remained mildly hyperparathyroid
and several were mildly hypoparathyroid by the IRMA PTH assay.
Bone histomorphometry in five subjects post-PTX showed either nor-
mal or low turnover. Radiologically, striking remineralization was seen
with disappearance of all erosive changes. We suggest that residual
areas of parathyroid tissue are stimulated and continue to secrete
hormone even when all the discrete glands have been removed. It is
recommended that when indicated, and in the absence of aluminum
excess, total PTX without autotransplant should be the preferred form
of therapy for long-term dialysis patients.
Although numerous advances have been made in the man-
agement of patients with chronic renal failure, progressive bone
disease with or without hypercalcemia remains a problem in a
small but important minority. The recognition of aluminum-
associated bone disease has identified one subset of individuals
which can be readily characterized by clinical features and
aluminum accumulation on bone histopathology [1—31. Al-
though secondary hyperparathyroidism usually co-exists with
aluminum bone disease, the more severe forms of secondary
hyperparathyroidism tend not to be associated with aluminum
toxicity as aluminum has a direct depressant effect on parathy-
roid gland (PIG) function both in vitro and in vivo [4—61.
The management of patients with secondary hyperparathy-
roidism has included control of serum inorganic phosphorus
levels and administration of vitamin D metabolites, usually 1,25
dihydroxyvitamin D3 (I ,25(OH)2D1), either by mouth or intra-
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venously [7]. In spite of these measures massive glandular
enlargement sometimes occurs necessitating parathyroidec-
tomy (PTX). Stanbury, Lumb and Nicholson in 1960 described
subtotal parathyroidectomy in two patients with chronic renal
failure [8], and numerous papers since then have reported its
use in patients on long term dialysis [9—13]. Ogg in 1967
described four patients with chronic renal failure who were
treated by total parathyroidectomy [14] and in 1973 discussed
its application to patients on dialysis [15]. Isolated reports of
complete glandular removal occur in the literature [16—27] but
either subtotal or more recently total parathyroidectomy with
autotransplantation of gland fragments has become the usual
treatment [28—31].
Subtotal or total parathyroidectomy with autotransplant will
lead to clinical improvement in most patients but it has become
clear that several problems remain [32]. These include: 1.)
persistant severe hyperparathyroidism. When this occurs one
or more glands have usually been overlooked; however, it is not
possible to be certain of this unless the remaining gland frag-
ments are completely removed and residual function assessed.
2.) There is a gradual development of recurrent hyperparathy-
roidism. This may be due to either progressive enlargement of
the residual or transplanted gland fragments or to hyperplasia of
unrecognized parathyroid tissue remnants. 3.) There could be
transplantation of parathyroid carcinoma into the arm or malig-
nant transformation of benign gland fragments. There is no
evidence that the latter occurs and the former remains a rare
possibility. 4.) The final problem is permanent hypoparathy-
roidism.
In several instances we have encountered persistent and/or
recurrent hyperparathyroidism following either subtotal or total
parathyroidectomy with transplantation, which led us to pro-
spectively evaluate elective total parathyroidectomy alone.
This paper describes the clinical experience with this approach
in nine patients and an additional one (Case 5) in whom 2.5
glands were removed but whose subsequent course indicated
that the remnant never functioned.
Methods
All patients with chronic renal failure who were parathyroid-
ectomized for secondary hyperparathyroidism in this center
from January 1984 to October 1988 were included. Nine pa-
tients were electively parathyroidectomized with removal of all
identifiable parathyroid tissue. Each of the three surgeons was
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Table I. Clinical data on patients
Age
Case Sex years Renal disease
I F 61 10 Hyperpara0
2 F 33 Hereditary nephritis
3 F 58 CON0
4 F 74 Unknown
5 F 67 CON
6 F 71 PKD
7 M 43 CON
8 M 30 CON
9 M 33 ON
10 F 30 Diabetic
a 10 Hyperparathyroidis and nephrocalcinosisb HBD, Severe hyperparathyroid bone disease
H, Hemodialysis
d CAPD, continuous ambulatory peritoneal dialysis
CON, Chronic glomerulonephritis
PKD, Polycystic kidney diseaseg NA, Not available
Pre-dialysis Duration
renal dialysis
failure pre-PTX
years
8 10.1
6 0.4
14 1.4
4 2.5
8 9.2
5 0.8
9 10.1
9.5
NA 13.5
1.0 7.6
3.6 HBDb
0.7 Hypercalcemia
2.4 HBD
0.1 HBD
14.6 HBD
1.6 Calciphylaxis
4.6 HBD
0.6 HI3D
0.6 HBD
0.4 HBD
Current status
Deceased
Alive with transplant
Alive
Deceased
Alive
Alive
Alive
Deceased
Alive
Alive
Table 2. Operative findings and course
specially interested and competent to perform this type of
operation. Clinical details are given in Table 1. Case 5 had a
subtotal removal 14 years previously, but was included because
of similar findings as well as having a prolonged duration of
observation. Hemodialysis was carried out by standard tech-
niques using Gambro 120 M Dialyzers (Gambro, Inc., Barring-
ton, Illinois, USA), acetate dialyzate and Gambro or Hospal
(Hospal Medical Corp., East Brunswick, New Jersey, USA)
proportioning equipment. Water for dialyzate preparation was
pre-treated by reverse osmosis followed by deionization and
contained less than 10 j.gIliter of aluminum. The dialysis
schedule was four hours three times a week. Patients on
continuous ambulatory peritoneal dialysis (CAPD) used 2 liters
of lavage solution four times daily. Dialyzate calcium was 1.56
mmol/liter and in peritoneal solution 1.75 mmol/liter. Prior to
parathyroidectomy aluminum-containing phosphate binders
were prescribed in varying amounts (Table 2), but subsequently
they were not used.
Biochemistry
Biochemistry and carboxyl (C) terminal parathyroid hormone
(PTH) were routinely measured in the laboratory using standard
Auto-Analyzer methods and the Diagnostic Systems Labora-
tory kit (Wester, Texas, USA) for immunoassayable parathy-
Duration
dialysis
post-PTX Reason
for PTX
Type of
dialysis
H'
CAPD
CAPD
H
H
CAPD
H
H
H
H
Case number 1 2 3 4 5
A
6 7 8 9 10
Surgeon A B A+B A B A C C C
No. operations 2 I 2h I I I I I I I
No. glands removed 4 4 7 4 2 ,5C 4 4 4 4 4
Total gland wt g >4.4 3.7 NAd 8 NA 2.5 14.2 3.6 3.1 1.9
Lowest serum ionized 0.77 1.03 0.56 0.96 NA 1.00 0.73 0.73 0.79 0.81
Ca mm/liter
Day lowest ionized Ca 3 22 3 7 2 I 3 3 10 8
Symptomatic hypocalcemia Yes No Yes No No No Yes Yes No No
Mean oral Ca supplement in hospital 2.3 0 1.4 2.0 2.5 2.4 1.8 1.8 2.0 2.6
giday
Current oral Ca supplement glday
Mean l,25(OH)2D1 in hospital tg/day
2.8
4.0
1.60
0
1.6
3.0
—
2.0
1.0
0.4 mg
0.4
2.0
1.5
2.3
2.0
3.0
3.0
3.0
3.0
3.0
Duration l,25(OH)2D3 days 425 0 485 31 ISO 34 395 134 228 149
Years off l,25(OH)2D3 14.3 3.5 2.9 0 1.1 1.4 0 0 0 0
Mean intravenous Ca g/day 0 0 0.2 0 0 0 0.3 0.6 0.2 0,3
Duration, days — — 8 — — — 14 9 6 4
Days in hospital post-PTX 9 5 13 14 8 9 16 12 10 8
Thymectomy No Yes No Yes No Yes No Yes Yes No
Phosphate binders pre-PTX g/day Al 3.0 1.0 0 0 0 0.5 0.3 0 0.4 0.4
a Parathyroid adenoma resected 18 yrs previously
b 5 glands removed at first PTX, 2 glands removed 4 months later
Subtotal PTX, 3 glands identified
' NA = not available
Prior to renal transplant; now in 2.0 g calcium daily
Dihydrotachysterol
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roid hormone (iPTH). Ionized calcium was measured in serum
using a Nova II analyzer. Intact and amino terminal PTH was
measured in a single assay using the appropriate kit (Immuno
Nuclear Corp., Stillwater, Minnesota, USA). in addition serum
intact PTH levels were measured in a single assay in seven
patients several months or years following PTX using the
Allegro immunoradiometric (IRMA) assay (Nichols Institute,
San Juan Capistano, California, USA) specific for the intact,
secreted, biologically active molecule [33, 34]. A C terminal
PTH radioimmunoassay, developed by one of us (P.D'A) at
Saint Luc Hospital, in Montreal, was also used to characterize
the parathyroid function of our patients. This assay has been
described before [35]. For normal patients the range is 40 to 200
pg/mI. Patients with chronic renal failure who are hemodialyzed
or on peritoneal dialysis have values between 1000 and 1500 pg/
ml due to accumulation of PTH fragments, even if they have
good control of calcium and phosphorus. Values above 1500 pg/
ml reflect secondary hyperparathyroidism, while values below
1000 pg/mi are seen in aluminum intoxication or after parathy-
roidectomy. This assay together with a cytochemical bio-assay
of P1'H was used to evaluate parathyroid responsiveness in two
individuals, Cases 5 and 7, 12 and 2 years post-P'I'X after
exposure to low and high calcium dialysate. They were selected
because of their low C terminal values. Serial samples were
taken; the baseline and final value are reported in Table 5. An
additional study of suppressibility was carried out using an
infusion of 15 mg/kg of calcium as calcium gluconate intrave-
nously over four hours immediately prior to a scheduled dialy-
sis. The cytochemical bioassay of PTH was carried out by Dr.
N. Loverige, Kennedy Institute, London [361.
Bone density
This was measured by dual energy X-ray absorptiometry
using the Lunar DPX equipment (Lunar Radiation Corp.,
Madison, Wisconsin, USA) in all patients still alive at the end of
the study period, together with a group of dialysis patients
selected for marked secondary hyperparathyroidism but who
had not been parathyroidectomized.
Bone histomorphometry
Bone biopsies were taken within 3.5 months preceeding PTX
(mean 1.5 0.5) from the anterior iliac crest following double
tetracycline labelling, and were processed as described previ-
ously [37]. Trephine cores were fixed in 1:1 10% buffered
formalin phosphate and 0.5% sucrose solution for two hours,
then dehydrated in propanol and embedded in glycol methac-
rylate at 4°C. Two-micrometer thick sections were cut for
routine morphometry and 8 jim thick sections for fluorescence.
Routine sections were stained for acid phosphatase and coun-
terstained with Harris hematoxylin. Osteoclasts appear bright
red, mineralized bone purple and osteoid light pink. Aluminum
was stained using the ammonium salt of aurintricarboxylic acid,
aluminon [38]. Morphologic countours were traced using a
projection system and cursor (Zeiss MOP-3 Oberkochen,
FRG), except for the fluorescent images which were photo-
graphed first and then projected. Measured parameters were
total bone as percent of tissue area, osteoid, tetracycline and
aluminum as percent trabecular surface, fibrous tissue as per-
cent marrow, and osteoclasts/mm trabecular surface. Bone
formation rate was calculated as: [distance between labels x
(length of double + length of single label)] ÷ time between
labels, and is expressed as js/day/mm2 of tissue.
Mineralization lag time was calculated as: osteoid width ÷
(distance between labels ÷ time between labels), and is ex-
pressed as days.
Normal values shown in Table 3 were obtained from 14
healthy subjects. Six subjects were tetracycline labelled and all
14 were analyzed for the remaining morphometric parameters.
Results
Post-operative course
1. Early. The early course was straightforward in all patients,
Table 2. Hypocalcemia developed in each instance, but in Case
2 it did not develop until day 22, 17 days after discharge from
the hospital. All patients except Case 2 received supplemental
oral calcium and a vitamin D compound. In eight instances this
was 1,25(OH)2D3 which was started two to five days pre-
operatively using a dose of 0.5 to 3 jig/day. Patients were
encouraged to drink one to two liters of milk daily starting on
the first post-operative day both for its calcium and phosphorus
content. Dialysis schedules remained unchanged. The severity
and duration of hypocalcemia was related to the pre-existing
bone disease (Fig. I).
Bone pain when present disappeared following surgery and
pruritis improved. Case 6 who had ulcerated skin lesions healed
these completely and Case 2 operated on for hypercalcemia
became normocalcemic. Case 4 was readmitted to hospital 10
days following discharge for fatigue and left arm weakness. She
died unexpectedly and was found to have endocarditis due to S.
epidermidis; its duration was uncertain but could possibly have
antedated surgery.
2, Late. Case 1 died suddenly 3.6 years post-PTX and
autopsy showed severe calcific aortic valve disease. Three
discrete nests of parathyroid cells were identified in the neck.
Case 2 was transplanted 8 months post-PTX. Three weeks later,
without any supplements, her serum ionized calcium had
dropped to 0.92 mmol/liter without any rise in P'fH which was
90 pg/mI (St. Luc assay for normals is 40 to 200). She was
placed on 2 glday oral calcium and her current values are 1.03
mmol/liter for ionized and 2.19 mmol/liter for total calcium,
with IRMA PTH of 29 pg/mI. Serum creatinine is 220 jim/liter.
Case 8 died following drug overdose in another part of the
country 6.5 months after PTX.
No evidence of recurrent disease has appeared in any of the
patients although C-PTH levels are elevated in Cases I and 3.
Bone histomorphometry
All patients had evidence of hyperparathyroidism pre-opera-
tively with increased numbers of osteoclasts, Table 3. Tetracy-
cline surface was increased except in Cases 2 and 4. The low
normal value in Case 2 was notable, which combined with the
striking hypercalcemia led us to initially question the diagnosis,
although similar cases have been described previously [231.
Bone pathology was obtained in six patients following surgery.
In Case 3 this was an autopsy sample; it showed a doubling of
osteoid surface with an increase in aluminum surface from 4 to
26.8% in four weeks even though there had not been any
aluminum intake. This patient was the only one known to have
previously had significant aluminum exposure and her initial
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course has been reported elsewhere in more detail [39]. How-
ever, because her aluminum surface was so low pre-operatively
and because she had not taken any aluminum during her time on
dialysis, no attempt was made to remove residual aluminum.
Following parathyroidectomy all bone parameters were in the
normal or low normal range except for Case I, who remains
mildly hyperparathyroid. Case 3, 5 and 7 are of interest because
1.5, 11 and 2 years after PTX without any medication except for
oral calcium and with low PTH and I ,25(OH)2D3 levels of 9 to
13 pg/mI, (normal range: 28 to 58 pg/mI) their bone formation
although low was still measurable; osteoid was not increased
and mineralization was occurring normally. Total bone area
was unchanged following PTX, but as osteoid area decreased
mineralized area actually increased. Direct evidence that a
considerable amount of new mineralized bone had been formed
was provided by the subsequent histomorphometry in patients
who had tetracycline labelling prior to PTX. In all five subjects
where tissue was available (Cases 1,2, 3,4 and 7), the old labels
were present, buried within the trabecular bone, Figure 2.
Parathyroid hormone status
This was evaluated using four different assays (Table 4). C
terminal was markedly elevated before PTX, being at least forty
times normal in all subjects. N terminal was measured in one
subject pre-PTX and the St. Luc's assay was measured in five
subjects. All were elevated. Following PTX Cases 2, 4, 5, 7, 8,
9 and 10 had normal C terminal levels. Except for Case 1 all had
normal N terminal where this was measured. With the St. Luc
assay, four patients had values above the normal range and five
within, although all had values below those expected for their
chronic renal failure. Case 4 had low levels. These samples
were in a freezer which failed over a weekend and they are
probably artefactually low. Four known hypoparathyroid pa-
tients were assayed at the same time, one was 40 pg/mI and the
others were less than 32 pg/mI. Using the IRMA Allegro assay,
of the seven patients tested Case 3 was high, Cases 2 and 10
were normal and Cases 5, 6, 7 and 9 were below the normal
range of 10 to 65 pg/mI. However, as the ionized calciums on
the same sample were low in Cases 2 and 10, 1.02 and 0.83
mmol/liter, respectively, this indicates an inadequate parathy-
roid response for six of the seven patients tested.
To further define the parathyroid status on Cases 5 and 7 they
were dialyzed against either a dialyzate calcium of zero or 2.2
mmol/liter, Table 5. The two subjects were chosen because
their C PTH levels were in the low normal range. Because of the
possibility that the changes seen might have been a non-specific
effect of dialysis rather than the result of a change in ionized
calcium levels, suppression was repeated using calcium infu-
sion as described in the Methods section. Bioactive PTH was
measured on selected samples in London and these results are
also shown in Table 5. Calcium infusion, either by dialysis or
directly, suppressed immunoreactive PTH. This was confirmed
by the bioactive PTH measurements which became undetect-
able in Case 7 and almost so in Case 5. Stimulation using the
zero calcium dialyzate dropped the ionized calcium to 27% and
24%, respectively, of baseline, yet the immunoreactive PTH
showed no rise and even tended to fall in both cases. However,
bioactive PTH rose in each instance from 0.7 to 23.3 for Case 5
and 2.0 to 4.9 for Case 7. It was concluded that both patients
had responsive residual parathyroid tissue.
Table 3. Bone histomorphometry
OC/mm' % Bone % Osteoid % Fibr." % Al % Tetra.' B.F.R.d M.L.T.e
Normal values (0.01—0.15) (16.5—54.7)(3.2—25.8) (0) (0) (3,8—13) (141—413) (12—24)
I Pre-PTX 1.42 36.2 32.9 13.5 0.9 34.6 1491 8.1
1 yr post 0.71 27.3 16.0 0.7 0 4.3 157 5.5
2 Pre-PTX 1.43 18.7 29.6 1.2 0 1.4 NA NA
1.5 yr post 0.32 32.8 38.9 0.07 0 24.9 440.4 24.3
3 Pre-PTX 1.80 41.2 43.2 96.9 0 49.4 2821 20.5
1.5 yr post 0.16 26.0 5.3 0 0 3.2 115 8.3
4 Pre-PTX 0.86 31.1 21.9 4.0 4.0 14.5 1464 8.8
0.1 yr post 0,12 13.3 45.6 0.7 26.8 NA NA NA
5 Pre-PTX NA NA NA NA NA NA NA NA
11.5 yr post 0.40 20.6 11.7 0 8.2 1.6 49 17.9
6 Pre-PTX 0.60 22.9 34.0 2.7 0 32.5 308 36.2
7 Pre-PTX 1.52 54.4 19.6 10.7 0 21.1 923 12.4
I yr post 0.10 44.9 7.3 0.2 0 2.2 141 6.5
2.3 yr post 0.08 56.0 3.9 0 0 0.4 17 13.0
8 Pre-PTX 1.19 34.2 59.8 56.7 0 52.2 4337 10.2
9 Pre-PTX 0.85 41.0 70.0 78.0 0 39.0 1719 17.8
10 Pre-PTX 1.90 30.0 77.2 23.0 0 64.7 2370 12.8
Mean pre-PTX
SE, N = 9 1.29 0.15 34.4 3.5 43.1 7.0 31.9 12 0.54 0.44 34.4 6.6 1314 389 14.3 2.4
Mean post-PTX
SE, N = 5 0.30 0.10 29.3 6.0 20.2 7.2 0.2 0.1 5.8 4.4 6.9 4.6 156 75 13.8 3.4
P <0.001 NS <0.05 <0.05 NS <0.01 <0.01 NS
a Osteoclasts/mm
b % Fibrosis
% Tetracyclined Bone formation rate .t2/d/mm2 tissue
Mineralization lag time in days
Fig. 2. Fluorescent photograph of second bone biopsy from Case 2.
Short white arrowheads show mineralized bone surface with double
tetracycline labels on the left border from the second biopsy. Similar
labels on right hand surface but cut obliquely. Split large arrowheads
shows bone formed in the 19 month interval between the two biopsies.
Stars show tetracycline from first biopsy. 8 m section, magnification x
100.
0
—10 —30
% Change Ionized Calcium
—50
Fig. 1. Relationship between the fall in ionized calcium following PTX
and pre-operative osteoclast count. The fall in ionized calcium post-
operatively is dependent on the severity of the pre-existing hyperpara-
thyroid bone disease.
Biochemistry
Table 4 shows the current biochemistry as compared with
that before PTX. Five patients had elevated total calcium levels
and four had elevated ionized calcium before operation. Post-
PTX the values are normal for total calcium in six and slightly
below normal in three. Ionized calcium was slightly low in four
cases. The fall in calcium post-operatively (Table 2) was related
to the pre-existing bone disease and correlated closely with the
osteoclast count (Fig. 1). Alkaline phosphatase was elevated in
all except Case 2 and fell to normal except for Cases 4, and 5.
Case 4 died prematurely. Case 5 had a cholecystectomy and
subsequently required common duct exploration and drainage,
her alkaline phosphatase increasing at that time to 436 U/liter.
In all patients urea and creatinine levels were unchanged.
Serum inorganic phosphorus levels following surgery were
almost normal pre-dialysis without any phosphate binders ex-
cept for the modest doses of oral calcium.
Radiology
Follow-up x-rays, after a sufficient time interval and if
initially showing signs of osteitis fibrosa, invariably demon-
strated striking remineralization and disappearance of cystic
lesions and erosions (Fig. 3). The rapid rate of healing was
notable, and this was demonstrated by Case 8 whose radiograph
is almost normal four months post-PTX. Radiological improve-
ment persisted in all patients on subsequent films and was seen
in all skeletal areas including long bones, hands and skull.
Bone densitometry
Except for Case 9 bone densitometry was only done at the
end of the study period. Vertebral bone mineral density (BMD)
was markedly increased to 1.288 0.072 g/cm2 or 112.6 3.7%
of age matched controls and showed no tendency to decrease
with time following PTX. Cases 3, 5 and 6 were post-meno-
pausal yet had values at or above the normal for age matched
females. For comparison 11 patients (mean age 54 3.1 years)
on dialysis 8.3 2.0 years with marked hyperparathyroidism
had a mean C PTH of 91.5 30.5 nglml (normal <1.3 ng/ml)
and a BMD of 1.137 0.05, 99.4 5,0% of age matched
controls.
Discussion
Type of operation
The literature is extensive in dealing with the types of surgical
approach to patients with secondary hyperparathyroidism in
end-stage renal disease. While some authors are convinced that
total parathyroidectomy with autotransplant is clearly the su-
perior form of treatment [32], others have preferred to continue
to perform subtotal PTX [40, 41]. Reviewers of both types of
approach surveying several hundred cases have concluded that
similar results are found from either treatment. Symptoms are
generally improved, however, recurrence of hyperparathyroid-
ism occurred in 6% of 439 patients in the world's literature as
reviewed by Niederle, Roka and Brennan in 1982 and 6.4% in
Saxe's review of 265 patients in 1984 following autotranspian-
tation [42 43]. Rothmund in 1986 reviewed the same literature
and added his own series [32]. There were 340 patients who
underwent subtotal PTX with a follow-up incidence of hyper-
calcemia of 8 to 40%. With PTX and autotransplant in 827 cases
.
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Table 4. Biochemistry bone mineral density and parathyroid hormone status before and after surgery
Ca Ca Pi P'tase Urea Creat N-PTH St.Luc
mmol/ mmol/ m,nol/ UI mmol/ pmolI C-PTH pmo!/ C-PTH IRMA Bonea L2-
liter liter liter liter liter liter ngmlml liter pgm/ml PTH density L4a
2.25— 1.15— 0.80— 30— 3.0— 40— 0.4— 0— 40— 20— % age BMD
Units normal values 2.64 1.28 1.45 110 8.9 330 1.3 9.6 200 65 matched g/cm2
Case
I Pre-P1'X 2.65 1.39 1.78 843 18.6 645 49 — — — — —
At death 2.48 1.25 1.58 77 27.8 875 29.5 19.9 647 — — —
2 Pre-PTX 3.65 1.93 1.68 Ill 19.6 114 75 — 1643 — — —
Currentd 2.65 1.23 1.81 86 26.4 1397 1.5 1.9 139 29 III 1.393
3 Pre-PTX 2.53 1.23 1.58 2158 28.9 804 335 — 5742 — — —
Current 2.54 1.15 1.18 76 28.5 1130 10 5.5 303 102 124 1.336
4 Pre-PTX 2.78 1.45 2.55 701 31.4 972 87 — 468bc — —
At death 2.15 1.19 0.94 754b 30.3 893 1.4 — 15bc — —
5 Pre-PTX 2.78 — 2.07 123 21.4 884 — — — — — —
Current 2.22 1.38 1.14 129 17.5 739 0.8 1.1 113 6 97 0.972
6 Pre-PTX 2.07 1.24 2.26 187 23.6 654 80 — 1161 — — —
Current 2.37 1.54 1.13 167 14.0 674 1.4 8.9 424 7 108 1.079
7 Pre-P1'X 2.80 1,38 2.07 810 17.1 875 47 — — — — —
Current 2.67 1.17 1.57 50 29.1 1395 0.7 0.9 214 2 115 1.376
8 Pre-PTX 2.43 1.28 2.37 553 25.6 778 228 486 3984 — — —
At death 2.10 1.02 1.19 90 45.7 3267 0.2 — 74 — — —
9 Pre-PTX 2.36 1.15 1.17 552 26.0 1208 174 — 9284 — 122 1.465
Current 2.06 1.02 1.48 66 24.5 1010 0.7 94 7 125 3.501
10 Pre-PTX 2.28 1.21 2.06 3090 38.0 1117 170 — 4400 — — —
Current 2.03 1.00 1.41 363 34.7 3009 0.6 — 63 II 308 1.358
Pre-PTX mean SE, 2.63 1.36 1.96 713 25.0 905 116 — 4369 — — —
N= 10 0.14 0.08 0.13 191 2.0 62 21 — 1210 — — —
Current mean SE, 2.33 1.20 1.34 100 27.9 1039 4.7 6.4 230 23 112.6 1.288
N = 10 0.88 0.05 0.09 14 2.8 81 2.9 3.0 66 13 3.7 0.072
P NS NS <0.001 <0.01 NS NS <0.001 — <0.001 — — —
a Bone mineral density, lumbar spine
b Not used for calculation of current mean
C May have lost some activity due to storage
d Prior to transplant
Table 5. Dynamic evaluation of parathyroid function
High calcium
Parameter Low calcium dialyzatea dialyzatet'
measured Normal values Time Case 5 Case 7 Case 5 Case 7
Calcium infusionC
Case 5 Case 7
Ionized l.l5—1.2Ommol.L zero 1.21 1.12 1.23 1.09 1.15 1.15
calcium final 0.88 0.85 1.47 1.57 1.59 1.59
% change —27.3 —24.1 + 19.5 +44 +38.3 +38.3
St. Luc PTH 40—200 pg/mI zero 112 338 82 448 113 214
final 73 302 69 342 54.8 169
% change —34.8 —10.7 —15.9 —23.7 —51.5 —21.5
Bioactive PTH 1—IS pg/mI zero 0.7 2.0 — —
final 23.3 4.9 — —
7.7 0.1
0.3 UDd
%change +3229 +145 —
-
—
—96.! —
a Final time 50 minutes
b Final time 60 minutes
C Final time 4 hours but bioactive measured at 60 minutes. Initial and final calciums happen to be the same in these two patients although the
intermediate values differed slightly
d Undetectable
the figure was 3 to 14%. As the follow-up period in most series articles detail the transplantation of parathyroid tissue into the
was less than five years and hypercalcemia is restricted to arm in patients subsequently diagnosed as having parathyroid
severe disease it is likely that this recurrence rate is a minimal carcinoma, clearly an undesirable event [45—48]. A recent
figure. review of the pathology of parathyroid autografts has confirmed
Although the initial report of malignant-like changes in trans- that aggressive muscle invasion and recurrent nodular hyper-
planted tissue [441 has not been confirmed and the validity of plasia can occur [49].
the original report is criticized [32], nevertheless at least four Where persistent or recurrent hyperparathyroidism is pres-
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Fig. 3. Phalangea! changes before and following PTX. A. Case I. Before and 3.5 years post.PTX. B. Case 3. Before and 1.5 years postPTX. C.
Case 5. 12.5 years post-PTX (22 years on dialysis) showing normal bone. D. Case 7. Before and I year post PTX. E. Case 8. Before and 4 months
post PTX. F. Case 9. Before and 8 months post PTX. C. Case 10. Before and 5 months post PTX. Arrows point to areas of bone loss which are
replaced following PTX. No pre-PTX film available for case 5. Subsequent films in case 7 are unchanged.
ent, evaluation is difficult if not impossible unless the trans-
planted tissue is removed. A gradient in PTH values between
the two arms proves that the graft is functional, but the absence
of a gradient could be due to variations in venous drainage and
sampling so that the presence of a graft can complicate the
recognition of residual, overlooked functioning tissue in the
neck.
Similar reasoning applies to subtotal PTX. Takagi et al who
compared the two procedures in 43 patients comments that
although similar clinical improvement occurred in both groups
post-parathyroidectomy recurrence of secondary hyperpara-
thyroidism can be anticipated whether the parathyroidectomy is
subtotal or total with parathyroid autotransplantation" [50],
Resulting from our own similar experiences we therefore de-
cided to prospectively evaluate total parathyroidectomy alone.
In a recent review it was commented that: "Total parathy-
roidectorny alone, advocated in earlier years, has meanwhile
been abandoned, since remineralization of bone is not possible
in the absence of PTH and the patient must undergo a life-long
supplemental treatment with vitamin D metabolites and oral
calcium" [32]. This statement needs careful examination as we
believe it is inaccurate, and that the viewpoint may explain why
total PTX has not been widely accepted. Following the original
paper in 1967 by Ogg [14] sporadic patients were reported in the
literature treated by total PTX [16—27]. Without exception the
results appeared to be satisfactory [51, and M.K. Ward, per-
sonal communication]. Recently Farrington et al reported on
the follow-up of seven patients treated by total PTX six to nine
years previously [52]. Only one person had undetectable iPTFI
levels; four were normal and three were elevated, two of whom
had evidence of hyperpar'athyroid bone disease. Our results are
essentially confirmatory of their findings. In a report of 21
patients treated by hemodialysis for more than 10 years, 8 of
whom had had a PTX, Piraino et al measured PTH levels in 15
patients. Case 13 was the only one with normal levels of C
terminal PTH and the only patient treated by total parathyroid-
ectomy [53, B.M. Piraino, personal communication].
In none of our eight patients could we show the total absence
of immunoreactive PTH in serum after total parathyroidec-
tomy. Results obtained with the St. Luc C terminal assay,
where in renal failure expected values have been derived from
several years of clinical observation, indicate that none of our
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patients had enough parathyroid tissue left to maintain PTH
levels as high as usually seen in patients on long-term dialysis.
Furthermore, in subjects 5 and 7, the remaining parathyroid
tissue was responsive to calcium modulation. Our conclusion is
that it is very difficult (or perhaps impossible) to completely and
permanently remove all parathyroid tissue in patients with renal
failure. The reason for this is presumably the continued strong
parathyroid stimulus associated with renal failure combined
with the previously expressed view that small discreet nests of
parathyroid cells can become functional given a strong and
persistent stimulus [54]. It is debatable whether the residual
tissue is an accessory or supernumerary gland or poorly cir-
cumscribed nests of cells. The latter were found at autopsy in
Case 1. As extra glands are only found in 13% of normal
subjects [55, 56] it would be statistically very unlikely that all
ten patients would have them. In any event leaving glandular
tissue behind deliberately, either in the neck or arm is unnec-
essary if, following total PTX, residual activity persists. Al-
though functional parathyroid reserve following total PTX is
less and some patients are mildly hypoparathyroid this is not of
clinical significance if they are given oral calcium combined
with regular equilibration with dialyzate calcium.
Bone dynamics
A central issue is the state of bone turnover following total
PTX or in the analogous situation of hypoparathyroidism with-
out renal disease. With regard to the latter it is remarkable how
little evidence there is of bone disease. Dreczner and colleagues
in reporting a patient with primary hypoparathyroidism and
osteomalacia commented on the rarity of clinical bone disease
in hypoparathyroidism [57]. It was suggested that the hypocal-
cemia was responsible for the mineralization defect. Woods
similarly noted either normal bone or excessive osteoid [58].
The evidence suggests that parathyroid deficiency without renal
disease leads to either normal bones [591 or osteomalacia, the
latter related to the level of serum calcium. In renal failure the
evidence that aluminum accumulation can cause osteomalacia
is substantial and as well, that parathyroidectomy can worsen
or precipitate aluminum bone disease by reducing new bone
formation, hence increasing the surface deposition of aluminum
[60—62]. Case 4 illustrates this phenomenon. It is important to
recognize that false negative results can be given by the
aluminon stain and we were misled by the absence of staining in
this patient. The staining technique will be the subject of a
separate report [63]. However, it is suggested that in the
absence of aluminum storage and with maintenance of close to
normal serum calcium and phosphorus levels that parathyroid
bone disease heals and the new bone is structurally normal. The
"buried" tetracycline from the pre-PTX biopsy provides addi-
tional direct evidence that substantial new mineralized bone
formation has taken place. Figure 2 shows the biopsy in Case 2,
who is mildly hypoparathyroid, 18 months post-PTX and 10
months following renal transplantation. Active bone formation
is occurring as shown by the double tetracycline labels and the
new bone formed between the first and second biopsies is
clearly apparent.
From the five bone biopsies with tetracycline labelling ob-
tained following PTX it was seen that bone formation was low
in each case, but resorption was also low as shown by the
osteoclast counts. These findings are similar to those reported
by Charhon et al who noted a sixfold decrease in tissue level
bone formation rate, (excluding the patients with aluminum
storage), following either subtotal parathyroidectomy or total
with transplant [64].
The impressive remineralization of the skeleton, Figure 3,
confirms that formation exceeded resorption so that in the final
analysis what counts is not the level of turnover but rather the
overall balance between formation and resorption. Concerning
this, the striking rise in whole body calcium measured by
neutron activation analysis, in six patients after total PTX
reported by Naik et al [65], illustrates the skeletal restoration
taking place with this treatment. This is confirmed by the bone
densitometry which shows no loss of bone mineral following
PTX and probably some increase, Table 4.
Post-operative care and medication following PTX
The final point made by Rothmund in the previous quotation
[32] refers to the lifelong needs for vitamin D and calcium. In
fact none of the patients needed vitamin D after the initial
post-operative period of hypocalcemia was corrected and the
skeleton was remineralized. While it could be maintained that
the aim of treatment should be to suppress any remaining
parathyroid tissue, and that the best way to do that would be to
maintain high normal ionized calcium levels combined with
administration of I ,25(OH)2H3, we have followed a different
approach. Attainment of close to normal calcium and phospho-
rus values, particularly the latter, without the use of aluminum
containing phosphate binders has been the goal. Recurrence of
significant parathyroid bone disease has been assumed to be
unlikely, if all glands were found and removed. By avoiding use
of vitamin D analogues, phosphate absorption was reduced and
modest amounts of oral calcium were sufficient to maintain
close to normal calcium and phosphorus levels. With these it
was hoped that remineralization would take place and meta-
static soft tissue calcification would not occur. These aims
appear to have been achieved. This approach does not negate
the use of vitamin D compounds if required and some centers
use them more readily than ourselves, however, serum phos-
phorus levels in conjunction with vitamin D are higher than the
ideal.
Our practice for post-operative care depends on the severity
of the bone disease. If this is mild, as in Case 2, we give no
calcium or vitamin D unless the serum calcium drops below 2
mmol/liter or symptoms appear. With severe, high turnover
bone disease, 1,25(OH)2D3 is started five days pre-operatively
in a dose of 3 pg/day, two liters of milk is offered from the day
of surgery, and oral calcium carbonate and calcium gluconoga-
lactogluconate given to provide a total of 3 to 4 g of elemental
calcium. Ionized calcium is measured twice daily and if it falls
below I mmol/liter a continuous intravenous infusion of calcium
is started using calcium gluconate to provide 10 to 20 mmol (400
to 800 mg) elemental calcium daily. The lowest serum calcium
level is usually on the third post-operative day and by the end of
the first week sufficient calcium is being absorbed from the
intestine that the infusion can be tapered and stopped. As noted
by Felsenfeld [66] and others [67] the extent of the fall in serum
calcium post-PTX is related to the extent of the bone disease
(Figure 1). It is interesting to note that the fall in serum calcium
was similar in our patients to those reported by Felsenfeld, as
shown by the similar slopes in our Figure 1 and their Figure 3,
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Biochemical changes following PTX
Previous studies have shown a relationship between the
severity of the bone disease and the drop in both serum calcium
and phosphorus following PTX and autotransplantation. Our
results were similar to these, indicating that the level of bone
turnover rather than the type of operation determines the
severity of hypocalcemia. Of course an incomplete operation
with an overlooked gland will be associated with a smaller fall
in serum calcium or no calcium at all. A transitory rise in serum
alkaline phosphatase occurs following surgery and has been
previously noted in several reports [68, 69].
Conclusions
Where proper indications exist and significant aluminum
storage is not present, there remains a small but important need
for PTX in patients with end-stage renal disease. We have
presented evidence that total parathyroidectomy without auto-
transplant, originally proposed 20 years ago, should be recon-
sidered as the preferred treatment because there is less likeli-
hood of recurrent hyperparathyroidism and because of the ease
of medical management with normalization of serum calcium
and phosphorus. While we believe these conclusions to be valid
for the patients who will remain on dialysis for a considerable
period of time, we have not considered the patient likely to be
transplanted in the near future (within 1 year). Our study does
not address this group, but as the stimulus to continued
parathyroid hyperfunction would be diminished following suc-
cessful transplantation, it might be reasonable to follow current
surgical thinking and carry out either a subtotal or total para-
thyroidectomy with autotransplant in these individuals. How-
ever, Case 2 has done very well at the time of writing (10
months post-renal transplant) with active new bone formation
(Fig. 2), although she is mildly hypoparathyroid. Finally, in
view of the controversy in this area, a prospective randomized
trial comparing total PTX alone with PTX and autotransplant
and/or subtotal PTX would be of considerable interest.
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